Bell's palsy during rechallenge of immune checkpoint inhibitor

IJU Case Reports

article

Kohji Takemura¹  Taro Yamanaka¹  Michikata Hayashida²  Rika Kizawa¹  Takeshi Yamaguchi¹  Yuko Tanabe¹  Kazushige Sakaguchi²  Koichi Suyama¹  Shinji Urakami²  Yuji Miura¹ 

[1] Department of Medical Oncology, Toranomon Hospital;Department of Urology, Toranomon Hospital

关键词: Bell's palsy;    immune-related adverse event;    nivolumab;    peripheral facial nerve palsy;    rechallenge of immune checkpoint inhibitor;   

DOI  :  10.1002/iju5.12572

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

IntroductionThe peripheral nervous system is one of the target organs of immune-related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known. Case presentationA man with renal cell carcinoma who received rechallenging immune checkpoint inhibitor therapy developed unilateral facial palsy and was diagnosed with Bell's palsy. He did not have any severe immune-related adverse events during his previous immune checkpoint inhibitor treatment. Corticosteroid therapy was immediately initiated, and his facial palsy symptoms promptly improved. ConclusionPhysicians should be aware that Bell's palsy can occur as an immune-related adverse event. Additionally, careful observation is necessary during rechallenge with immune checkpoint inhibitors, even in patients who did not have previous immune-related adverse events.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND